- Reuters•6 days ago
India's small and medium-sized generic drugmakers say the threat of tougher rules and higher barriers for outsiders in the U.S. healthcare market will force many to find a niche or focus their expansion efforts on other countries. Cut-price generics sold by India's small- and medium-sized drugmakers have been critical in bringing down prices there. A more protectionist stance by President Donald Trump, with the prospect of import tariffs and the U.S. boosting local drug manufacturing, mean the operating environment for smaller generic players will get worse, executives at Indian companies said.
- PR Newswire•7 days ago
MONMOUTH JUNCTION, N.J., March 16, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), manufacturer of the CytoSorb® extracorporeal blood purification therapy that reduces excessive levels of inflammatory mediators in critically-ill and cardiac surgery patients, announced today that they have entered into a partnership with Dr. Reddy's Laboratories Ltd for the South African market. Under the terms of the agreement, Dr. Reddy's has the exclusive rights to distribute CytoSorb for intensive care, cardiac surgery, and other hospital applications in South Africa.
- PR Newswire•last month
BASEL, Switzerland, February 8, 2017 /PRNewswire/ -- Dr. Reddy's Laboratories Ltd announced today the expansion of its commercial operations in Europe with the introduction of its portfolio of generics ...
DRREDDY.NS : Summary for DR REDDYS LABS INR5 - Yahoo Finance
Dr. Reddy's Laboratories Limited (DRREDDY.NS)
NSE - NSE Real Time Price. Currency in INR
Add to watchlist
|Day's Range||2,620.00 - 2,647.70|
|52 Week Range||2,555.20 - 3,689.85|
|PE Ratio (TTM)||45.85|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|